Golimumab 50 and 100 mg , administered subcutaneously ( SC ) every 4 weeks ( q4wk ) , were assessed in patients with active RA ( methotrexate-nave , methotrexate-experienced and anti-TNF ( tumour necrosis factor ) - experienced ) , PsA or AS , despite conventional therapy .